Search hospitals > Texas > Dallas
Medical City Dallas Hospital
Claim this profileDallas, Texas 75230
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Lymphoma
Conducts research for Sarcoma
Conducts research for Lymphoblastic Leukemia-Lymphoma
284 reported clinical trials
5 medical researchers
Summary
Medical City Dallas Hospital is a medical facility located in Dallas, Texas. This center is recognized for care of Leukemia, Tumors, Lymphoma, Sarcoma, Lymphoblastic Leukemia-Lymphoma and other specialties. Medical City Dallas Hospital is involved with conducting 284 clinical trials across 434 conditions. There are 5 research doctors associated with this hospital, such as Stanton C. Goldman, Bruce Bowers, M.D., Vivian Dimas, MD, and Todd Dewey, M.D..Area of expertise
1Leukemia
Global LeaderStage II
NTRK1 positive
NTRK positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Stanton C. GoldmanMedical City Dallas Hospital7 years of reported clinical research
Expert in Tumors
Expert in Lymphoma
56 reported clinical trials
104 drugs studied
Bruce Bowers, M.D.Medical City Dallas5 years of reported clinical research
Studies Mitral Valve Regurgitation
Studies Mitral Regurgitation
3 reported clinical trials
6 drugs studied
Vivian Dimas, MDMedical City Children's Hospital2 years of reported clinical research
Studies Congenital Heart Defects
Studies Heart Disease
3 reported clinical trials
4 drugs studied
Todd Dewey, M.D.Medical City Dallas5 years of reported clinical research
Studies Aortic Valve Stenosis
Studies Mitral Valve Regurgitation
2 reported clinical trials
4 drugs studied
Clinical Trials running at Medical City Dallas Hospital
Germ Cell Tumors
Osteosarcoma
Brain Tumor
Acute Lymphoblastic Leukemia
Rhabdomyosarcoma
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Acute Leukemia
Tumors
Neuroblastoma
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical City Dallas Hospital?
Medical City Dallas Hospital is a medical facility located in Dallas, Texas. This center is recognized for care of Leukemia, Tumors, Lymphoma, Sarcoma, Lymphoblastic Leukemia-Lymphoma and other specialties. Medical City Dallas Hospital is involved with conducting 284 clinical trials across 434 conditions. There are 5 research doctors associated with this hospital, such as Stanton C. Goldman, Bruce Bowers, M.D., Vivian Dimas, MD, and Todd Dewey, M.D..